Medical Aspects of Chemical Warfare (2008) - The Black Vault

Medical Aspects of Chemical Warfare159. Cucinell SA. Review of the toxicity of long-term phosgene exposure. Arch Environ Health. 1974;28:272–275.160. Polednak AP. Mortality among men occupationally exposed to phosgene in 1943–1945. Environ Res. 1980;22:357–367.161. Diller WF, Zante R. Dose-effect relations in the effects of phosgene on man and animals. Literature review. Zentralblattfuer Arbeitsmedizin, Arbeitsschutz, Prophylaxe Ergonomie. 1982;32:360–4, 366–368.162. Pastore A, Federici G, Bertini E, Piemonte F. Analysis of glutathione: implication in redox and detoxification. Clin ChimActa. 2003;333:19–39.163. Richie JP Jr, Skowronski L, Abraham P, Leutzinger Y. Blood glutathione concentrations in a large-scale human study.Clin Chem. 1996;42:64–70.164. Reed DJ, Fariss MW. Glutathione depletion and susceptibility. Pharmacol Rev. 1994;36(suppl 2):25–33.165. Pohl LR., Branchflower RV, Highest RJ, et al. The formation of diglutathionyl dithiocarbonate as a metabolite of chloroform,bromotrichloromethane, and carbon tetrachloride. Drug Metab Dispos. 1981;9:334–339.166. Fabrizi L, Taylor GW, Edwards RJ, Boobis AR. Adducts of the chloroform metabolite phosgene. Adv Exp Med Biol.2001;500:129–132.167. Anders MW, Stevens JL, Sprague RW, Shaath, Z, Ahmed AE. Metabolism of haloforms to carbon monoxide. II. In vivostudies. Drug Metab Dispos. 1978:6:556–560.168. Sciuto AM, Strickland PT, Kennedy TP, Gurtner GH. Postexposure treatment with aminophylline protects againstphosgene-induced acute lung injury. Exp Lung Res. 1997;23:317–332.169. Sciuto AM, Hurt HH. Therapeutic treatments of phosgene-induced lung injury. Inhal Toxicol. 2004;16:565–580.170. Sciuto AM. Assessment of early acute lung injury in rodents exposed to phosgene. Arch Toxicol. 1998;72:283–288.171. Sciuto AM, Cascio MB, Moran TS, Forster JS. The fate of antioxidant enzymes in bronchoalveolar lavage fluid over 7days in mice with acute lung injury. Inhal Toxicol. 2003;15:675–685.172. Kubic VL, Anders MW. Metabolism of carbon tetrachloride to phosgene. Life Sci. 1980;26:2151–2155.173. Gwilt PR, Radick LE, Li XY, Whalen JJ, Leaf CD. Pharmacokinetics of 2-oxothiazolidine-4-carboxylate, a cysteineprodrug, and cysteine. J Clin Pharmacol. 1998;38:945–950.174. Pastore A, Massoud R, Motti C, et al. Fully automated assay for total homocysteine, cysteine, cysteinylglycine, glutathione,cysteamine and 2-mercaptopropionylglycine in plasma and urine. Clin Chem. 1998;44:825–832.175. Boettcher B, Meister A. Synthesis of L-2-oxothiazolidine-4-carboxylic acid. Anal Biochem. 1984;138:449–450.176. Porta P, Aebi S, Summer K, Lauterburg BH. L-2-oxothiazolidine-4-carboxylic acid, a cysteine prodrug: pharmacokineticsand effects on thiols in plasma and lymphocytes in human. J Pharmacol Exp Ther. 1991;257:331–334.177. Kling A. Acute pulmonary edema following exposure to war gases. Comptes Rendus De L’Academie des Sciences.1933;197:1782–1784.178. Cowlen MS, Hewitt WR, Schroeder F. 2-hexanone potentiation of [14C]chloroform hepatotoxicity: covalent interactionof a reactive intermediate with rat liver phospholipid. Toxicol Appl Pharmacol. 1984;73:478–491.179. De Biasi A, Sbraccia M, Keizer J, Testai E, Vittozzi L. The regioselective binding of CHCI3 reactive intermediates tomicrosomal phospholipids. Chem Biol Interact. 1992;85:229–242.180. Guastadisegni C, Guidoni L, Balduzzi M, Viti V, Di Consiglio E, Vittozzi L. Characterization of a phospholipid adductformed in Sprague Dawley rats by chloroform metabolism: NMR studies. J Biochem Mol Toxicol. 1998;12:93–102.750